Phaseline

Companies › FoRx Therapeutics

FoRx Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FORX-428
PARG inhibitor
PARGPhase 1Advanced Solid TumorsJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07356453FORX-428Phase 1Advanced Solid TumorsOncologyJun 2027

Targets

PARG (1)

Companies with the same targets

Evopoint Biosciences 858 Therapeutics IDEAYA Biosciences

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.